Tufts CSDD
Facing high innovation risk, costs, and inefficiencies, sponsor companies have increasingly engaged in establishing risk-sharing partnerships, including joint ventures, mergers and acquisitions, in-licensing, and co-development arrangements.
To understand collaboration practices and preferences, the Tufts Center for the Study of Drug Development (Tufts CSDD) examined the development and approval histories of 289 drugs approved by the FDA between 2000 through 2011. Of these drugs, half involved a collaborative development arrangement, with licensing deals being the most common risk-sharing approach.
A quarter of these collaborations were part of a merger, acquisition, or co-development arrangement. Tufts CSDD also found that the prevalence for risk-sharing collaborations varied by therapeutic area, with approved central nervous system drugs having the highest prevalence.
The growth of collaborative risk-sharing innovation models will likely accelerate in a drug-development operating environment characterized by scientifically and logistically complex and demanding protocols, low success rates, and high R&D investments that are targeting smaller market opportunities.
— Tufts Center for the Study of Drug Development, http://csdd.tufts.edu/.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.